Abstract
Mortalin, a mitochondrial chaperone, plays a crucial role in reducing toxicity of Lewy bodies. Earlier studies had reported that Mortalin level gets downregulated in astrocytes and other brain tissue samples in Parkinson’s disease (PD). This study aims to estimate the Mortalin concentration in serum and correlate with α-synuclein (α-Syn) in PD. The concentration of Mortalin and α-Syn in serum samples of 38 PD patients and 33 control group (CG) individuals was quantified by surface plasmon resonance. The receiver operating characteristic curves were plotted to develop it as blood-based protein marker. The expression of Mortalin in serum was validated by western blot. The Mortalin level was found to be declined in PD patients (1.98 ± 0.53 ng/µL) in comparison with CG individuals (3.13 ± 0.48 ng/µL), whereas α-Syn level was found to be elevated in PD patients (38.20 ± 4.22 ng/µL) than CG individuals (34.31 ± 3.23 ng/µL) in serum. The statistical analysis revealed the negative correlation between Mortalin and α-Syn. This preliminary study summarized that Mortalin plays a significant role in PD with negative correlation with α-Syn. This study provides a new paradigm for the development of Mortalin as a potent serum protein marker for diagnosis of PD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- α-Syn:
-
α-Synuclein
- UPDRS-III:
-
Unified Parkinson’s disease Rating Scale-III
- Hsp:
-
Heat-shock protein
- SPR:
-
Surface plasmon resonance
- ROC:
-
Receiver operating characteristic
References
Anderson, N. L., & Anderson, N. G. (2002). The human plasma proteome: History, character, and diagnostic prospects. Molecular and Cellular Proteomics, 1(11), 845–867. https://doi.org/10.1074/mcp.R200007-MCP200.
Cook, T. J., Hoekstra, J. G., Eaton, D. L., & Zhang, J. (2016). Mortalin is expressed by astrocytes and decreased in the midbrain of Parkinson’s disease patients. Brain Pathology, 26(1), 75–81. https://doi.org/10.1111/bpa.12274.
Flower, T. R., Chesnokova, L. S., Froelich, C. A., Dixon, C., & Witt, S. N. (2005). Heat shock prevents alpha- synuclein- induced apoptosis in a yeast model of Parkinson’s disease. Journal of Molecular Biology, 351(5), 1081–1100. https://doi.org/10.1016/j.jmb.2005.06.060.
Greenamyre, J. T., & Hastings, T. G. (2004). Biomedicine: Parkinson’s—Divergent causes, convergent mechanisms. Science, 304(5674), 1120–1122. https://doi.org/10.1126/science.1098966.
Gupta, B. M., & Bala, A. (2013). Parkinson’s disease in India: An analysis of publications output during 2002-2011. International Journal of Nutrition, Pharmacology, Neurological Diseases, 3(3), 254–262. https://doi.org/10.4103/2231-0738.114849.
Hwang, O. (2013). Role of oxidative stress in Parkinson’s disease. Experimental Neurobiology, 22(1), 11–17. https://doi.org/10.5607/en.2013.22.1.11.
Jin, J., Hulette, C., Wang, Y., Zhang, T., Pan, C., Wadhwa, R., et al. (2006). Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: Relevance to Parkinson disease. Molecular and Cellular Proteomics, 5(7), 1193–1204. https://doi.org/10.1074/mcp.M500382-MCP200.
Liu, Y., Liu, W., Song, X. D., & Zuo, J. (2005). Effect of GRP75/mtHsp70, PRP74/mortalin over expression on intracellular ATP level, mitochondrial membrane potential and ROS accumulation following glucose deprivation in PC12 cells. Molecular and Cellular Biochemistry, 268(1–2), 45–51.
Nuytemans, K., Theuns, J., Cruts, M., & Broeckhoven, V. C. (2010). Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Human Mutation, 31(7), 763–780. https://doi.org/10.1002/humu.21277.
Opazo, F., Krenz, A., Heermann, S., Schulz, J. B., & Falkenburger, B. H. (2008). Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. Journal of Neurochemistry, 106(2), 529–540. https://doi.org/10.1111/j.1471-4159.2008.05407.x.
Reed, T. T., Sultana, R., & Butterfield, D. A. (2010). Redox proteomics of oxidatively modified brain proteins in mild cognitive impairment. In O. Alzate (Ed.), Neuroproteomics. Frontiers in neuroscience. Boca Raton, FL: CRC Press.
Taylor, W. H. (1969). Serum enzymes in the diagnosis of disease. British Journal of Anaesthesia, 4(13), 227–234.
Thadikkaran, L., Siegenthaler, M. A., Crettaz, D., Queloz, P. A., Schneider, P., & Tissot, J. D. (2005). Recent advances in blood-related proteomics. Proteomics, 5(12), 3019–3034. https://doi.org/10.1002/pmic.200402053.
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A., Kasai, T., et al. (2010). Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 75(20), 1766–1772. https://doi.org/10.1212/WNL.0b013e3181fd613b.
Zhu, J., Vereshchagina, N., Sreekumar, V., Barbulla, L. F., Costa, A. C., Daub, K. J., et al. (2013). Knockdown of Hsc70-5/mortalin induces loss of synaptic mitochondria in a drosophila Parkinson’s disease model. PLoS ONE, 8(12), e83714. https://doi.org/10.1371/journal.pone.0083714.
Acknowledgements
This research did not receive any specific grant from funding agency in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared no conflict of interest.
Rights and permissions
About this article
Cite this article
Singh, A.P., Bajaj, T., Gupta, D. et al. Serum Mortalin Correlated with α-Synuclein as Serum Markers in Parkinson’s Disease: A Pilot Study. Neuromol Med 20, 83–89 (2018). https://doi.org/10.1007/s12017-017-8475-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-017-8475-5